Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track COLL with free AI briefings, catalyst countdowns, and dilution alerts.

COLL · COLLEGIUM PHARMACEUTICAL, INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$144.8M Cash on Hand
CF+ Cash Runway
Follow COLL by email Get an email when COLL reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about COLL, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Oxycodone
FDA approved Apr 2016 · Xtampza Er
Chronic Pain Phase 4 · NCT03588806 Terminated
Ticagrelor Unstable Angina Pectoris Phase 4 · NCT02939248 Completed
Morphine Unstable Angina Phase 4 · NCT04442919 Completed
Methoxyflurane Unstable Angina Phase 4 · NCT04442919 Completed
Rosuvastatin Hypercholesterolemia Phase 4 · NCT02772640 Completed
Levosimendan Systolic Heart Failure Phase 4 · NCT03764722 Unknown
Delayed-release, extended-release… ADHD Phase 4 · NCT07838311 Not yet recruiting
Switch to prasugrel 5 mg at day 45 Non ST Segment Elevation Acute Coronary Syndrome Phase 3 · NCT05779059 Unknown
De-escalation to prasugrel 5 mg at day 30 Non ST Segment Elevation Acute Coronary Syndrome Phase 3 · NCT05779059 Unknown
De-escalation to ticagrelor 60 mg at day 30 Non ST Segment Elevation Acute Coronary Syndrome Phase 3 · NCT05779059 Unknown
Switch to ticagrelor 60 mg at day 45 Non ST Segment Elevation Acute Coronary Syndrome Phase 3 · NCT05779059 Unknown
Oxycodone DETERx Chronic Low Back Pain Phase 3 · NCT01685684 Completed
Methoxyflurane - Penthrox ST Elevation Myocardial Infarction Phase 3 · NCT04476173 Unknown
Methylphenidate Attention Deficit Hyperactivity Disorder Phase 3 · NCT06431256 Terminated

Also used in these trials (approved or third-party drugs, not COLL's own candidates): Rifaximin, Aspirin, Empagliflozin, Evolocumab, Prasugrel.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

COLL holds $144.8M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when COLL files for a raise →

👥 Who Owns COLL

Insiders 13.5% Other 5%+ holders 7.7% Institutions (346 holders) 78.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Rubric Capital Management LP
10% owner
Insider 3,132,743 10.08% 2025-08-13
Millennium Management LLC 5%+ holder (13G) 2,400,985 7.73% 2026-09-30
STATE STREET CORPORATION Institution (13G, 5%+) 1,772,243 5.70% 2026-09-30
Vikram Karnani
President and CEO, Director
Insider 186,127 0.60% 2026-11-12
Colleen Tupper
EVP & Chief Financial Officer
Insider 147,282 0.47% 2026-02-10
John Gordon Freund
Director
Insider 115,706 0.37% 2026-05-18
Gino Santini
Director
Insider 112,483 0.36% 2026-06-08
Thomas B Smith
EVP and Chief Medical Officer
Insider 90,651 0.29% 2026-02-10
David Dieter
EVP & General Counsel
Insider 77,071 0.25% 2026-03-18
Scott Dreyer
EVP & Chief Commercial Officer
Insider 71,770 0.23% 2026-03-03
Garen G Bohlin
Director
Insider 71,000 0.23% 2026-05-14
John A. Fallon
Director
Insider 64,634 0.21% 2025-11-12

Share count 31,075,424 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full COLL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for COLL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.